Literature DB >> 23932921

DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.

Akio Iio1, Takeshi Takagi, Kohei Miki, Tomoki Naoe, Atsuo Nakayama, Yukihiro Akao.   

Abstract

In various human malignancies, widespread dysregulation of microRNA (miRNA) expression is reported to occur and affects various cell growth programs. Recent studies suggest that the expression levels of miRNAs that act as tumor suppressors are frequently reduced in cancers because of chromosome deletions, epigenetical changes, aberrant transcription, and disturbances in miRNA processing. MiR-143 and -145 are well-recognized miRNAs that are highly expressed in several tissues, but down-regulated in most types of cancers. However, the mechanism of this down-regulation has not been investigated in detail. Here, we show that DEAD-box RNA helicase 6, DDX6 (p54/RCK), post-transcriptionally down-regulated miR-143/145 expression by prompting the degradation of its host gene product, NCR143/145 RNA. In human gastric cancer cell line MKN45, DDX6 protein was abundantly expressed and accumulated in processing bodies (P-bodies). DDX6 preferentially increased the instability of non-coding RNA, NCR143/145, which encompasses the miR-143/145 cluster, and down-regulated the expression of mature miR-143/145. In human monocytic cell line THP-1, lipopolysaccharide treatment promoted the assembly of P-bodies and down-regulated the expression of NCR143/145 and its miR-143/145 rapidly. In these cells, cycloheximide treatment led to a loss of P-bodies and to an increase in NCR143/145 RNA stability, thus resulting in up-regulation of miR-143/145 expression. These data demonstrate that DDX6 contributed to the control of NCR143/145 RNA stability in P-bodies and post-transcriptionally regulated miR-143/145 expression in cancer cells.
© 2013.

Entities:  

Keywords:  5′-3′ exoribonuclease 1; 7-methylguanosine; 7mG; ACTB; AGO1; AGO2; ARE; AU-rich elements; ActD; Argonaute 1; Argonaute 2; CHX; CRM1; DAPI; DCP1 decapping enzyme homolog A; DCP1A; DDX17; DDX5; DDX6; DEAD-box RNA helicase 17; DEAD-box RNA helicase 5; DEAD-box RNA helicase 6; EDC3; GAPDH; HIF1A; IFN-β; IPZ; IgG; LMB; LPS; Lipopolysaccharide; NC; NCR143/145; NMD; P-bodies; PVDF; RACE; RIPA; RISC; RN7SL1; RNA 7SL cytoplasmic 1; RNA-induced silencing complexes; RNU6B; TNF-α; U22 snoRNA host gene; U6 small nuclear B RNA; UHG; XRN1; actinomycin D; beta-actin; cycloheximide; diamidino-2-phenylindole; enhancer of mRNA decapping 3 homolog; glyceraldehyde-3-phosphate dehydrogenase; heterogeneous nuclear ribonucleoproteins; hnRNPs; hypoxia inducible factor 1 alpha subunit; immunoglobulin G; importazole; importin family nuclear export receptor; interferon-beta; leptomycin B; miR-143; miR-145; miRNA; microRNA; microRNA precursors; microRNA-143; microRNA-143/145 host non-coding RNA gene; microRNA-145; negative control; non-spliced NCR143/145; nonsense-mediated mRNA decay; nsNCR143/145; polyvinylidene fluoride; pre-miRNAs; pri-miRNAs; primary microRNA transcripts; processing bodies; r15-LOX; radioimmunoprecipitation assay; rapid amplification of cDNA ends; reticulocyte 15-lipoxigenase; tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2013        PMID: 23932921     DOI: 10.1016/j.bbagrm.2013.07.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

Review 1.  Long Noncoding RNA in Digestive Tract Cancers: Function, Mechanism, and Potential Biomarker.

Authors:  Shuo Zeng; Yu-Feng Xiao; Bo Tang; Chang-Jiang Hu; Rei Xie; Shi-Ming Yang; Bo-Sheng Li
Journal:  Oncologist       Date:  2015-07-08

2.  DEAD-box helicase 6 (DDX6) is a new negative regulator for milk synthesis and proliferation of bovine mammary epithelial cells.

Authors:  Zhen Zhen; Minghui Zhang; Xiaohan Yuan; Bo Qu; Yanbo Yu; Xuejun Gao; Youwen Qiu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-08-25       Impact factor: 2.416

Review 3.  The DEAD-box protein family of RNA helicases: sentinels for a myriad of cellular functions with emerging roles in tumorigenesis.

Authors:  Mohamed A M Ali
Journal:  Int J Clin Oncol       Date:  2021-03-03       Impact factor: 3.402

4.  Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.

Authors:  Cristina I Caescu; Xingyi Guo; Lydia Tesfa; Tushar D Bhagat; Amit Verma; Deyou Zheng; E Richard Stanley
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113

5.  Inhibition of SW620 human colon cancer cells by upregulating miRNA-145.

Authors:  Chen Li; Na Xu; Yu-Qiang Li; Yu Wang; Zhi-Tu Zhu
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

6.  microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.

Authors:  Gaetano Santulli
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 7.  Dysregulation of non-coding RNAs in gastric cancer.

Authors:  Qing Yang; Ren-Wen Zhang; Peng-Cheng Sui; Hai-Tao He; Lei Ding
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Assembly of a comprehensive regulatory network for the mammalian circadian clock: a bioinformatics approach.

Authors:  Robert Lehmann; Liam Childs; Philippe Thomas; Monica Abreu; Luise Fuhr; Hanspeter Herzel; Ulf Leser; Angela Relógio
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

Review 9.  Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis.

Authors:  Ani V Das; Radhakrishna M Pillai
Journal:  Cancer Cell Int       Date:  2015-09-29       Impact factor: 5.722

10.  Hypoxia activated long non-coding RNA HABON regulates the growth and proliferation of hepatocarcinoma cells by binding to and antagonizing HIF-1 alpha.

Authors:  Cheng-Ning Ma; Lu-Lu Wo; Di-Fei Wang; Ci-Xiang Zhou; Jing-Chi Li; Xin Zhang; Xiu-Feng Gong; Chen-Long Wang; Ming He; Qian Zhao
Journal:  RNA Biol       Date:  2021-01-21       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.